Today: 18 January 2026
Subscribe
Browse Category

Biotech News 11 November 2025 - 4 December 2025

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

As Tonix Pharmaceuticals transitions from clinical-stage hopeful to commercial biotech on the back of its new fibromyalgia drug Tonmya, Wall Street is split between blockbuster dreams and dilution fears. TNXP Stock on December 4, 2025: Price, Volume and Volatility Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) spent Thursday, December 4, 2025 trading around the high‑teens, with several data providers showing the…
4 December 2025
····
AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

AXSM Stock Today (Nov. 25, 2025): Axsome Therapeutics Near Record Highs on 63% Revenue Surge

New York — November 25, 2025 — Axsome Therapeutics (NASDAQ: AXSM) heads into Tuesday’s session trading just below fresh record highs, powered by blockbuster growth from its depression drug Auvelity, the launch of migraine pill Symbravo, and a rapidly expanding neuroscience pipeline. Shares closed on Monday, November 24, at $151.20, up 1.2% on the day and modestly higher in after-hours…
25 November 2025
··
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics (NASDAQ: VKTX) heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and above its original target. Viking Therapeutics InvestorRoom As of yesterday’s close (Monday, November 24), VKTX changed hands at $34.65, implying…
25 November 2025
···
BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Published: November 24, 2025Ticker: Bristol Myers Squibb Company (NYSE: BMY) Key takeaways This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. BMY stock today: a 4% move that stands out Bristol Myers Squibb shares climbed sharply on Monday, with BMY changing hands around $48.24, up roughly $1.99…
24 November 2025
····
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen Inc. (NASDAQ: BIIB) shares surged to fresh 52‑week highs on Monday, November 24, 2025, as investors reacted to a high‑profile Alzheimer’s drug failure at Novo Nordisk and a new immunology partnership with Dayra Therapeutics. By the closing bell, BIIB stock finished at $177.42, up about 1.2% from Friday’s close of $175.30. The stock traded as high as $185.17 intraday,…
24 November 2025
··
NeuBase Therapeutics (NBSE) Stock on November 23, 2025: Delisting, Liquidation Escrow and What Shareholders Still Need to Know

NeuBase Therapeutics (NBSE) Stock on November 23, 2025: Delisting, Liquidation Escrow and What Shareholders Still Need to Know

NeuBase Therapeutics stock is one of those tickers that still pops up on certain quote screens in late 2025 – but in reality, it isn’t a “normal” stock anymore. As of Sunday, November 23, 2025, NeuBase is a dissolved biotech in legal wind‑down, its common shares delisted and largely cashed out through liquidation payments and a non‑tradable escrow structure. MarketWatch…
23 November 2025
·
Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update

Arvinas (NASDAQ: ARVN) jumped in double digits on November 18, 2025 amid a focused pipeline reset, FDA momentum for vepdegestrant and attention at the Jefferies London Healthcare Conference. ARVN stock pops on November 18, 2025 Arvinas shares are in rally mode this Tuesday. By mid‑afternoon U.S. trading, ARVN is up more than 14% on the day, with intraday prices hovering…
18 November 2025
····
Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025

Aspire Biopharma (ASBP) Jumps on $100M Equity Line and Q3 Filing – What Matters on November 14, 2025

Micro‑cap biotech Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is back in the spotlight today after securing a new $100 million equity line of credit and releasing its Q3 2025 10‑Q, sending the stock sharply higher in pre‑market trading. ASBP stock among Friday’s biggest pre‑market movers Aspire Biopharma shares were one of the most active health‑care names in U.S. pre‑market trade…
14 November 2025
··
Invivyd (IVVD) Rockets Over 50% Pre‑Market on November 14, 2025 as Traders Rush Into COVID Antibody Play

Invivyd (IVVD) Rockets Over 50% Pre‑Market on November 14, 2025 as Traders Rush Into COVID Antibody Play

Invivyd, Inc. (NASDAQ: IVVD) is back in the spotlight this Friday, November 14, 2025, with its stock exploding higher in pre‑market trading on the back of building momentum around its COVID‑19 antibody franchise and recent earnings. By early morning, IVVD was one of the most actively watched biotech names on Wall Street. Invivyd stock today: IVVD among top pre‑market gainers…
14 November 2025
··
Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (NASDAQ: OTLK) shares jumped today after the U.S. FDA accepted the company’s resubmitted Biologics License Application (BLA) for ONS‑5010/LYTENAVA, its bevacizumab-based eye drug for wet AMD, and set a PDUFA review date of December 31, 2025. Here’s what investors need to know. What Outlook Therapeutics announced today This morning, Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced that the U.S.…
13 November 2025
···
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress

Published: November 11, 2025 Viking Therapeutics, Inc. (NASDAQ: VKTX) steps into the spotlight today with a scheduled fireside chat at the Stifel 2025 Healthcare Conference in New York (4:40–5:10 p.m. ET). The appearance comes on the heels of new clinical analyses from ObesityWeek® 2025 and an October corporate update outlining steady Phase 3 progress for its lead obesity candidate, VK2735.…
11 November 2025
···
Vor Biopharma (VOR) Prices $100M Stock Offering at $10; Shares Slide as Investors Weigh Dilution — Nov. 11, 2025

Vor Biopharma (VOR) Prices $100M Stock Offering at $10; Shares Slide as Investors Weigh Dilution — Nov. 11, 2025

What happened today Vor Biopharma Inc. (NASDAQ: VOR) priced an underwritten public offering of 10 million common shares at $10.00 per share for $100 million in expected gross proceeds. The company granted underwriters a 30‑day option to purchase up to 1.5 million additional shares. Vor expects the transaction to close on or about Wednesday, Nov. 12, 2025, subject to customary…
11 November 2025
···
1 … 4 5 6 7 8 … 12

Stock Market Today

  • Q3 Media Earnings: fuboTV Leads as Group Beats Estimates; WMG and WBD Mixed
    January 18, 2026, 3:28 PM EST. Q3 media earnings show resilience amid secular headwinds. Seven tracked stocks beat revenue estimates by an average of 2.1%, and shares rose about 6.2% on the quarter. The standout was fuboTV, which posted revenue of $377.2 million, down 2.3% year over year but topping consensus by 4.9%; the company also beat EPS and EBITDA forecasts, though the stock has fallen 28.9% since results and trades near $2.69. Warner Music Group delivered revenue of $1.87 billion, up 14.6% YoY and topping estimates by 10.8%; the stock rose about 1.2% to $30.88. By contrast, Warner Bros. Discovery reported revenue of $9.05 billion, down 6% YoY and missing content revenue estimates by 1.9%, but beat adjusted operating income expectations; the stock has risen 24.5% to around $28.52.
Go toTop